No Data
Endurant Capital Management LP Purchases 184,705 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)
Endurant Capital Management LP increased its stake in shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) by 165.2% during the 1st quarter, according to its most recent Form 13F filing with t
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Acadian Asset Management LLC
Acadian Asset Management LLC raised its stake in Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) by 65.7% in the first quarter, according to the company in its most recent disclosure with the Secur
Sutro Biopharma Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, Sutro Biopharma's (NASDAQ:STRO) reported sales totaled $28.10 million. Despite a 33.49% increase in earnings, the company posted a loss of $26.01 millio
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-form
GSA Capital Partners LLP Has $291,000 Stake in Sutro Biopharma, Inc. (NASDAQ:STRO)
GSA Capital Partners LLP trimmed its stake in Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) by 50.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchan
Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $21.00 by Analysts at Truist Financial
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target trimmed by Truist Financial from $37.00 to $21.00 in a research note published on Tuesday, The Fly reports. The firm currently has a bu
Sutro Biopharma Price Target Cut to $21.00/Share From $37.00 by Truist Securities
Sutro Biopharma Price Target Cut to $21.00/Share From $37.00 by Truist Securities
Sutro Biopharma Is Maintained at Buy by Truist Securities
Sutro Biopharma Is Maintained at Buy by Truist Securities
Sutro Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 08/23/2022 245.39% Truist Securities $37 → $21 Maintains Buy 05/23/2022 130.26% Piper Sandler $29 → $14 Ma
Sutro Biopharma (NASDAQ:STRO) PT Lowered to $21.00
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target cut by Truist Financial from $37.00 to $21.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Truist
Loading...
